PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on July 22, 2025, the Compensation Committee of Guardantâs Board of Directors approved the granting of restricted stock units (âRSUsâ) representing 239,565 shares of its common stock to 189 new non-executive employees and two non-qualified stock option awards to purchase 23,542 shares of its common stock to two new non-executive employees with a grant date of August
Related Questions
Will the compensation expense from these grants materially impact the companyâs next quarter or fiscal year earnings guidance?
How will the issuance of 239,565 RSUs and 23,542 NQSOs affect Guardant Healthâs share dilution and earnings per share?
What is the expected vesting schedule and any lockâup periods for these new employee awards?
How does the size and structure of this employee compensation package compare to recent grants by peer oncology or precisionâmedicine companies?
Could the addition of 189 new nonâexecutive employees signal a strategic expansion that might influence revenue growth forecasts?
What is the marketâs perception of the Nasdaq Listing Rule 5635(c)(4) inducement grantsâare they viewed as a positive retention tool or a potential source of future selling pressure?
Will any of the newly granted shares be eligible for early exercise or resale, potentially increasing shortâterm supply in the market?
How might the compensation committeeâs approval of these awards affect analyst sentiment and target price revisions for Guardant Health?
Are there any tax or accounting implications associated with the RSU and NQSO grants that could affect cash flow or balanceâsheet metrics?
What is the historical price reaction to similar employee compensation announcements for Guardant Health and its industry peers?